Most Favored Patient Act of 2026
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Most Favored Patient Act of 2026, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Government Operations, Trade.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H5941EECFE9E74C84841FEAAB600D1A7B: 1. Short title This Act may be cited as the Most Favored Patient Act of 2026.
- Section H425F9F883E4D44E8BA39BBE184DF3DE4: 2. Requiring the Center for Medicare and Medicaid Innovation to test a model implementing most favored nation drug pricing Section 1115A of the Social Security...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Most Favored Patient Act of 2026, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Government Operations, Trade
Primary Purpose
This bill, Most Favored Patient Act of 2026, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeReferred to the Committee on Energy and Commerce, and in …
Introduced in House
Mr. Meuser introduced the following bill; which was referred to …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
Key Definitions
Terms defined in this bill
any of the following countries: Canada. Denmark. France. Germany. Italy. Japan. Switzerland. The United Kingdom. The term specified drug means— a covered outpatient drug (as defined in section 1927(k))
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology